volanesorsen sold brand name waylivra triglyceridereducing drug chimeric antisense therapeutic oligonucleotide targets messenger rna apolipoprotein apociii common side effects include reduced platelet levels reactions site injection pain swelling itching volanesorsen antisense oligonucleotide short piece synthetic rna type genetic designed block production protein slows breakdown fats called apolipoprotein blocking production protein medicine reduces level triglycerides blood result fat accumulation body expected reduce risk familial chylomicronaemia syndrome fcs also known type hyperlipoproteinaemia inherited disease people abnormally high levels types fat called triglycerides excess fat accumulates organs spleen liver become abnormally fat accumulation also cause repeated bouts pancreatitis inflammation pancreas xanthomas formation yellow fatty deposits skin generally around volanesorsen indicated adjunct diet adults genetically confirmed familial chylomicronemia syndrome fcs high risk pancreatitis response diet triglyceride lowering therapy phase iii clinical trials treatment hypertriglycidemiawhen familial chylomicronemia syndrome familial partial drug discovered developed ionis pharmaceuticals volanesorsen designated orphan drug european medicines agency ema february phosphorothioate oligonucleotide targeted apolipoprotein ciii treatment familial chylomicronaemia volanesorsen approved medical use european union may volanesorsen effective reducing triglycerides blood study participants familial chylomicronemia syndrome three months participants given volanesorsen average reduction level triglycerides compared average increase participants given placebo dummy participants study lowfat diet addition receiving volanesorsen complete sequence volanesorsen volanesorsen international nonproprietary name httpsenwikipediaorgwikivolanesorsen